The structure of siRNA consists of short, double-stranded RNA molecules, typically 19-25 base pairs in length.

Interference RNA

RNA interference (RNAi) is a natural cellular mechanism that occurs in plants, animals and humans. It is mediated by small double-stranded RNA fragments called siRNAs that play a key role in gene regulation during development and in the immune response to viral infections.

Thanks to biotechnology, it is possible to harness this cellular process to design targeted RNAi-based therapies.

Some diseases are caused by protein malfunction or overproduction of proteins. The use of RNAi-based drugs makes it possible to reduce or specifically control the production of those involved in a pathology.

In 2006, the Nobel Prize in Physiology or Medicine was awarded jointly to Andrew Z. Fire and Craig C. Mello for their discovery of siRNA-mediated RNAi. Twelve years later, the first drug based on this technology was approved and made available to patients.

•

Small molecule RNA interference (siRNA) blocks, with high specificity, gene expression, the process by which information from a gene is used in the synthesis of a functional protein.

RNAi drugs use the cellular machinery in the cytoplasm to silence messenger RNAs (mRNAs), which are molecular precursors of proteins, and thus, without affecting genes, regulate their production for disease treatment benefit.

Interference RNA

RNA interference (RNAi) is a natural cellular mechanism that occurs in plants, animals and humans. It is mediated by small double-stranded RNA fragments called siRNAs that play a key role in gene regulation during development and in the immune response to viral infections.

Thanks to biotechnology, it is possible to harness this cellular process to design targeted RNAi-based therapies.

Some diseases are caused by protein malfunction or overproduction of proteins. The use of RNAi-based drugs makes it possible to reduce or specifically control the production of those involved in a pathology.

In 2006, the Nobel Prize in Physiology or Medicine was awarded jointly to Andrew Z. Fire and Craig C. Mello for their discovery of siRNA-mediated RNAi. Twelve years later, the first drug based on this technology was approved and made available to patients.

•

Small molecule RNA interference (siRNA) blocks, with high specificity, gene expression, the process by which information from a gene is used in the synthesis of a functional protein.

RNAi drugs use the cellular machinery in the cytoplasm to silence messenger RNAs (mRNAs), which are molecular precursors of proteins, and thus, without affecting genes, regulate their production for disease treatment benefit.